HER2 regulation of peroxisome proliferator-activated receptor γ (PPARγ) expression and sensitivity of breast cancer cells to PPARγ ligand therapy

Clinical Cancer Research

Volumn 9, Issue 8, 2003, Pages 3198-3203

  Yang, Zhibo ^a   Bagheri Yarmand, Rozita ^a   Balasenthil, Seetharaman ^a   Hortobagyi, Gabriel ^a   Sahin, Aysegul A ^a   Barnes, Christopher J ^a   Kumar, Rakesh ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRASTUZUMAB; TROGLITAZONE;

ARTICLE; BREAST; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL ANCHORAGE; CELL DIFFERENTIATION; CELL STRAIN MCF 7; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE C ERB; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; UPREGULATION;

ANTIBODIES, MONOCLONAL; AZO COMPOUNDS; BLOTTING, NORTHERN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE, TUMOR; CHROMANS; COLORING AGENTS; CYTOPLASM; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIGANDS; LIPID METABOLISM; LUCIFERASES; RECEPTOR, ERBB-2; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RNA, MESSENGER; THIAZOLIDINEDIONES; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 0042525804     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hortobagyi, G. N. Treatment of breast cancer. N. Engl. J. Med., 339: 974-984, 1998.
2. Baselga, J., and Norton, L. Focus on breast cancer. Cancer Cell, 1: 319-322, 2002.
3. Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., and Barcos, M. c-erbB2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med., 330: 1260-1266, 1994.
4. Borg, A., Baldetorp, B., Ferno, M., Killander, D., Olsson, H., Ryden, S., and Sigurdsson, H. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett., 81: 137-144, 1994.
5. Carraway, K., and Cantley, L. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell, 78: 5-8, 1994.
6. Kumar, R., Mandal, M., and Vadlamudi, R. New insights into anti-HER2 receptor monoclonal antibody research. Semin. Oncol., 27: 84-91, 2000.
7. Kurokawa, H., Lenferink, A. E., Simpson, J. E., Pisacane, P. I., Sliwkowski, M. X., Forbes, J. T., and Arteaga, C. L. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res., 60: 5887-5894, 2000.
8. Cuello, M., Ettenberg, S. A., Clark, A. S., Keane, M. M., Posner, R. H., Nau, M. M., Dennis, P. A., and Lipkowitz, S. Down-regulation of the erbB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res., 61: 4892-4900, 2001.
9. Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D'Andrea, G., Seidman, A., Norton, L., Gunnett, K., Falcey, J., Anderson, U., Waksal, H., and Mendelsohn, J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol., 18: 904-914, 2000.
10. Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., and Osborne, C. K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat., 24: 85-95, 1992.
11. Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., and Spiegelman, B. M. Terminal differentiation of human breast cancer through PPARγ. Mol. Cell, 1: 465-470, 1998.
12. Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., Evans, R. M., and Spiegelman, B. M. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc. Natl. Acad. Sci. USA, 94: 237-241, 1997.
13. Kitamura, S., Miyazaki, Y., Hiraoka, S., Nagasawa, Y., Toyota, M., Takakura, R., Kiyohara, T., Shinomura, Y., and Matsuzawa, Y. PPARγ agonists inhibit cell growth and suppress the expression of cyclin D1 and EGF-like growth factors in ras-transformed rat intestinal epithelial cells. Int. J. Cancer, 94: 335-342, 2001.
14. Sarraf, P., Mueller, E., Jones, D., King, F. J., DeAngelo, D. J., Partridge, J. B., Holden, S. A., Chen, L. B., Singer, S., Fletcher, C., and Spiegelman, B. M. Differentiation and reversal of malignant changes in colon cancer through PPAR γ. Nat. Med., 4: 1046-1052, 1998.
15. Mueller, E., Smith, M., Sarraf, P., Kroll, T., Aiyer, A., Kaufman, D. S., Oh, W., Demetri, G., Figg, W. D., Zhou, X. P., Eng, C., Spiegelman, B. M., and Kantoff, P. W. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc. Natl. Acad. Sci. USA, 97: 10990-10995, 2000.
16. Sarraf, P., Mueller, E., Smith, W. M., Wright, H. M., Kum, J. B., Aaltonen, L. A., de la Chapelle, A., Spiegelman, B. M., and Eng, C. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol. Cell, 3: 799-804, 1999.
17. Han, S. W., Greene, M. E., Pitts, J., Wada, R. K., and Sidell, N. Novel expression and function of peroxisome proliferator-activated receptor γ (PPARγ) in human neuroblastoma cells. Clin. Cancer Res., 7: 98-104, 2001.
18. Chang, T. H., and Szabo, E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer. Cancer Res., 60: 1129-1138, 2000.
19. Chang, T. H., and Szabo, E. Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-γ and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin. Cancer Res., 8: 1206-1212, 2002.
20. Talukder, A. H., Mandal, M., Vadlamudi, R. V., Mendelsohn, J., and Kumar, R. Regulation of elongation factor-1α expression by growth factors and anti-receptor blocking antibodies. J. Biol. Chem., 276: 5636-5642, 2001.
21. Mandal, M., Vadlamudi, R., Nguyen, D., Wang, R. A., Costa, L., Bagheri-Yarmand, R., Mendelsohn, J., and Kumar, R. Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J. Biol. Chem., 276: 9699-9704, 2001.
22. Bagheri-Yarmand, R., Mandal, M., Talukder, A. H., Wang, R. A., Vadlamudi, R. K., Kung, H. J., Kumar, R. Etk/Bmx tyrosine kinase activates Pakl and regulates tumorigenicity of breast cancer cells. J. Biol. Chem., 276: 29403-29409, 2001.
23. Barnes, C. J., Li, F., Mandal, M., Yang, Z., Sahin, A. A., and Kumar, R. Heregulin induces expression, ATPase activity, and nuclear localization of G3BP, a ras signaling component, in human breast tumors. Cancer Res., 62: 1251-1255, 2002.